Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial

J. Butler, A. Stebbins, V. Melenovský, NK. Sweitzer, MR. Cowie, J. Stehlik, MS. Khan, RO. Blaustein, JA. Ezekowitz, AF. Hernandez, CSP. Lam, R. Nkulikiyinka, CM. O'Connor, BM. Pieske, P. Ponikowski, JA. Spertus, AA. Voors, KJ. Anstrom, PW....

. 2022 ; 15 (6) : e009337. [pub] 20220603

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018117

BACKGROUND: We examined the effects of vericiguat compared with placebo in patients with heart failure with reduced ejection fraction enrolled in VICTORIA (Vericiguat Global Study in Patients With Heart Failure With Reduced Ejection Fraction) on health status outcomes measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) and evaluated whether clinical outcomes varied by baseline KCCQ score. METHODS: KCCQ was completed at baseline and 4, 16, and 32 weeks. We assessed treatment effect on KCCQ using a mixed-effects model adjusting for baseline KCCQ and stratification variables. Cox proportional-hazards modeling was performed to evaluate the effect of vericiguat on clinical outcomes by tertiles of baseline KCCQ clinical summary score (CSS), total symptom score (TSS), and overall summary score (OSS). RESULTS: Of 5050 patients, 4664, 4741, and 4470 had KCCQ CSS (median [25th to 75th], 65.6 [45.8-81.8]), TSS (68.8 [47.9-85.4]), and OSS (59.9 [42.0-77.1]) at baseline; 94%, 88%, and 82% had data at 4, 16, and 32 weeks. At 16 weeks, CSS improved by a median of 6.3 in both arms; no significant differences in improvement were seen for TSS and OSS between the 2 groups (P=0.69, 0.97, and 0.13 for CSS, TSS, and OSS). Trends were similar at 4 and 32 weeks. Vericiguat versus placebo reduced cardiovascular death or heart failure hospitalization risk similarly across tertiles of baseline KCCQ CSS, TSS, and OSS (interaction P=0.13, 0.21, and 0.65). CONCLUSIONS: Vericiguat did not significantly improve KCCQ scores compared with placebo. Vericiguat reduced the risk of cardiovascular death or heart failure hospitalization across the range of baseline health status. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02861534.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018117
003      
CZ-PrNML
005      
20220804134551.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1161/CIRCHEARTFAILURE.121.009337 $2 doi
035    __
$a (PubMed)35656822
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Butler, Javed $u Department of Medicine, University of Mississippi Medical Center, Jackson (J.B.)
245    10
$a Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial / $c J. Butler, A. Stebbins, V. Melenovský, NK. Sweitzer, MR. Cowie, J. Stehlik, MS. Khan, RO. Blaustein, JA. Ezekowitz, AF. Hernandez, CSP. Lam, R. Nkulikiyinka, CM. O'Connor, BM. Pieske, P. Ponikowski, JA. Spertus, AA. Voors, KJ. Anstrom, PW. Armstrong, VICTORIA Study Group
520    9_
$a BACKGROUND: We examined the effects of vericiguat compared with placebo in patients with heart failure with reduced ejection fraction enrolled in VICTORIA (Vericiguat Global Study in Patients With Heart Failure With Reduced Ejection Fraction) on health status outcomes measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) and evaluated whether clinical outcomes varied by baseline KCCQ score. METHODS: KCCQ was completed at baseline and 4, 16, and 32 weeks. We assessed treatment effect on KCCQ using a mixed-effects model adjusting for baseline KCCQ and stratification variables. Cox proportional-hazards modeling was performed to evaluate the effect of vericiguat on clinical outcomes by tertiles of baseline KCCQ clinical summary score (CSS), total symptom score (TSS), and overall summary score (OSS). RESULTS: Of 5050 patients, 4664, 4741, and 4470 had KCCQ CSS (median [25th to 75th], 65.6 [45.8-81.8]), TSS (68.8 [47.9-85.4]), and OSS (59.9 [42.0-77.1]) at baseline; 94%, 88%, and 82% had data at 4, 16, and 32 weeks. At 16 weeks, CSS improved by a median of 6.3 in both arms; no significant differences in improvement were seen for TSS and OSS between the 2 groups (P=0.69, 0.97, and 0.13 for CSS, TSS, and OSS). Trends were similar at 4 and 32 weeks. Vericiguat versus placebo reduced cardiovascular death or heart failure hospitalization risk similarly across tertiles of baseline KCCQ CSS, TSS, and OSS (interaction P=0.13, 0.21, and 0.65). CONCLUSIONS: Vericiguat did not significantly improve KCCQ scores compared with placebo. Vericiguat reduced the risk of cardiovascular death or heart failure hospitalization across the range of baseline health status. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02861534.
650    12
$a srdeční selhání $x diagnóza $x farmakoterapie $7 D006333
650    _2
$a heterocyklické sloučeniny bicyklické $7 D006574
650    _2
$a lidé $7 D006801
650    _2
$a pyrimidiny $7 D011743
650    _2
$a kvalita života $7 D011788
650    _2
$a tepový objem $7 D013318
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Stebbins, Amanda $u Duke Clinical Research Institute (A.S., A.F.H., K.J.A.), Duke University School of Medicine, Durham, NC
700    1_
$a Melenovský, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (V.M.)
700    1_
$a Sweitzer, Nancy K $u University of Arizona Sarver Heart Center, Tucson (N.K.S.)
700    1_
$a Cowie, Martin R $u Royal Brompton Hospital, London, United Kingdom (M.R.C.) $1 https://orcid.org/0000000174572552 $7 nlk20050168765
700    1_
$a Stehlik, Josef $u University of Utah School of Medicine, Salt Lake City (J.S.)
700    1_
$a Khan, Muhammad Shahzeb $u Division of Cardiology (M.S.K.), Duke University School of Medicine, Durham, NC
700    1_
$a Blaustein, Robert O $u Merck & Co., Inc, Kenilworth, NJ (R.O.B.)
700    1_
$a Ezekowitz, Justin A $u Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada (J.A.E., P.W.A.)
700    1_
$a Hernandez, Adrian F $u Duke Clinical Research Institute (A.S., A.F.H., K.J.A.), Duke University School of Medicine, Durham, NC
700    1_
$a Lam, Carolyn S P $u National Heart Centre Singapore, Duke-National University of Singapore (C.S.P.L.)
700    1_
$a Nkulikiyinka, Richard $u Bayer AG, Wuppertal, Germany (R.N.)
700    1_
$a O'Connor, Christopher M $u Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.)
700    1_
$a Pieske, Burkert M $u Charité University Medicine, German Heart Center, Berlin, Germany (B.M.P.)
700    1_
$a Ponikowski, Piotr $u Wroclaw Medical University, Poland (P.P.)
700    1_
$a Spertus, John A $u University of Missouri-Kansas City School of Medicine (J.A.S.)
700    1_
$a Voors, Adriaan A $u University of Groningen, the Netherlands (A.A.V.)
700    1_
$a Anstrom, Kevin J $u Duke Clinical Research Institute (A.S., A.F.H., K.J.A.), Duke University School of Medicine, Durham, NC
700    1_
$a Armstrong, Paul W $u Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada (J.A.E., P.W.A.) $1 https://orcid.org/0000000204603445
710    2_
$a VICTORIA Study Group
773    0_
$w MED00159985 $t Circulation. Heart failure $x 1941-3297 $g Roč. 15, č. 6 (2022), s. e009337
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35656822 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134545 $b ABA008
999    __
$a ok $b bmc $g 1821945 $s 1169360
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 15 $c 6 $d e009337 $e 20220603 $i 1941-3297 $m Circulation. Heart failure $n Circ Heart Fail $x MED00159985
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace